1. Home
  2. LMAT vs ELVN Comparison

LMAT vs ELVN Comparison

Compare LMAT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$100.82

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

HOLD

Current Price

$39.86

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
ELVN
Founded
1983
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
LMAT
ELVN
Price
$100.82
$39.86
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$105.80
$43.40
AVG Volume (30 Days)
210.9K
552.6K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
0.93%
N/A
EPS Growth
30.57
3.17
EPS
0.68
N/A
Revenue
$249,602,000.00
N/A
Revenue This Year
$14.21
N/A
Revenue Next Year
$8.88
N/A
P/E Ratio
$148.23
N/A
Revenue Growth
13.53
N/A
52 Week Low
$78.35
$14.79
52 Week High
$118.01
$48.53

Technical Indicators

Market Signals
Indicator
LMAT
ELVN
Relative Strength Index (RSI) 39.65 45.18
Support Level $82.65 $16.84
Resistance Level $114.98 $40.62
Average True Range (ATR) 5.12 2.46
MACD -1.08 -0.50
Stochastic Oscillator 26.42 19.51

Price Performance

Historical Comparison
LMAT
ELVN

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Share on Social Networks: